About CHEK2

The CHEK2 gene (Checkpoint Kinase 2) on chromosome 22q12 The hypomorphic 1100delC truncating mutation increases breast cancer risk ~2-fold and is present in ~1% of the European population. Key targets include Exons 2–15 for comprehensive mutation screening.

Mutations: 1100delC, I157T, S428F, del5395 | GC content: 52% | Target exons: Exons 2–15

CHEK2 Primer Design Challenges

  • Founder mutation 1100delC: The 1100delC frameshift in exon 10 causes premature truncation requiring specific genotyping primers
  • Multiple splice variants: Alternative splicing generates isoforms lacking kinase domain or FHA domain, requiring transcript awareness
  • Pseudogene interference: Processed pseudogene on chromosome 15 shares homology with CHEK2 exons 10–15

Recommended Primer Design Parameters for CHEK2

ParameterStandard ExonsOptimized Regions
Primer length20–22 nt22–25 nt
GC content45–55%50–60%
Tm58–62°C60–65°C
Amplicon size150–300 bp180–350 bp
Annealing temp58–60°C60–64°C (touchdown)
PCR additiveStandardOptional 3–5% DMSO for problematic regions

Recommended Primer Sequences for CHEK2

Target RegionForward Primer (5′→3′)Reverse Primer (5′→3′)Amplicon
Exon 10 (1100delC)5′-CAATATTGCTGTGGGAGTGC-3′5′-CCTGAGTCCACCTGTCCTTC-3′192 bp
Exon 3 (FHA domain)5′-GCCCAGACCATGTGTAAGGA-3′5′-ACAGGTTCATCATCGCAACA-3′167 bp

Key SNPs to Avoid in Primer Binding Sites

When designing CHEK2 primers, avoid these clinically significant variants:

  • rs555607708 (1100delC) — Exon 10 founder frameshift, breast cancer risk
  • rs17879961 (I157T) — Exon 3 missense, reduced kinase activity

Clinical Validation Required
All CHEK2 primers designed with VigyanLLM are for research use only. Clinical diagnostic applications require additional wet-lab validation, Sanger sequencing confirmation, and regulatory approval before patient use.

Design CHEK2 Primers Now

Pre-configured with CHEK2-specific parameters. Use our primer design, Tm calculator, and GC content tools for optimal results.

Design CHEK2 Primers → Tm Calculator GC Calculator